BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health@McCulloughFund@IIAR_Journals@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
If you weren’t sure what a “Color Revolution” is, this young lady does an excellent job explaining it.
We’ve been going through a “Color Revolution” in the United States since 2016. (I’m sure you can guess those involved).
Great one to bookmark and share.
@brysongray @Morris_Crichlow Jesus was completely filled with the Holy Spirit, which I interpret to mean that he had an overflowing measure of every gift and every fruit of the spirit.
Do you think it’s possible for a believer today to be given that same measure?
@SpartaJustice@JackPosobiec Ink on paper is not scripture.
Nuance, personhood, and relationship bring the Kingdom truth of scripture to life.
Jesus is ALIVE.
His fame grows with every passing generation.
He is still reaching into humanity.
Scripture is true like a window is true. What is the beauty beyond?
@Springs143@l42022425@Michael59302787 17 Therefore do not be unwise, but understand what the will of the Lord is.
18 And do not be drunk with wine, in which is dissipation; but be filled with the Spirit…
20 giving thanks always for all things to God the Father in the name of our Lord Jesus Christ
Ephesians 5